keyword
MENU ▼
Read by QxMD icon Read
search

CIBMTR

keyword
https://www.readbyqxmd.com/read/28869618/outcomes-following-autologous-hematopoietic-stem-cell-transplant-for-patients-with-relapsed-wilms-tumor-a-cibmtr-retrospective-analysis
#1
M H Malogolowkin, M T Hemmer, J Le-Rademacher, G A Hale, P A Metha, A R Smith, C Kitko, A Abraham, H Abdel-Azim, C Dandoy, M Angel Diaz, R P Gale, G Guilcher, R Hayashi, S Jodele, K A Kasow, M L MacMillian, M Thakar, B M Wirk, A Woolfrey, E L Thiel
Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively...
September 4, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28865971/haploidentical-hematopoietic-stem-cell-transplantation-for-myelodysplastic-syndrome
#2
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
This study aimed at validating the predictive ability of the Center for International Blood and Marrow Transplant Research (CIBMTR) prognostic scoring system on the outcomes of patients with myelodysplastic syndromes (MDS) who had received human leukocyte antigen (HLA)-haploidentical related donor hematopoietic stem cell transplantation (haplo-HSCT). We also tried to propose and validate a more suitable prognostic scoring system. A total of 157 patients with MDS, who received haplo-HSCT, were enrolled. The CIBMTR prognostic scoring system could predict the 2-year clinical outcomes after haplo-HSCT, but failed to predict the 100-day clinical outcomes after haplo-HSCT...
August 30, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28817182/centralized-patient-reported-outcome-data-collection-in-transplantation-is-feasible-and-clinically-meaningful
#3
Bronwen E Shaw, Ruta Brazauskas, Heather R Millard, Rachel Fonstad, Kathryn E Flynn, Amy Abernethy, Jenny Vogel, Charney Petroske, Deborah Mattila, Rebecca Drexler, Stephanie J Lee, Mary M Horowitz, J Douglas Rizzo
BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) cures many patients, but often with the risk of late effects and impaired quality of life. The value of quantifying patient-reported outcomes (PROs) is increasingly being recognized, but the routine collection of PROs is uncommon. This study evaluated the feasibility of prospective PRO collection by an outcome registry at multiple time points from unselected HCT patients undergoing transplantation at centers contributing clinical data to the Center for International Blood and Marrow Transplant Research (CIBMTR), and then it correlated the PRO data with clinical and demographic data...
August 17, 2017: Cancer
https://www.readbyqxmd.com/read/28811306/replication-and-validation-of-genetic-polymorphisms-associated-with-survival-after-allogeneic-blood-or-marrow-transplant
#4
Ezgi Karaesmen, Abbas A Rizvi, Leah Preus, Philip L McCarthy, Marcelo C Pasquini, Kenan Onel, Xiaochun Zhu, Stephen Spellman, Christopher A Haiman, Daniel O Stram, Loreall Pooler, Xin Sheng, Qianqian Zhu, Li Yan, Qian Liu, Qiang Hu, Amy Webb, Guy Brock, Alyssa I Clay-Gilmour, Sebastiano Battaglia, David Tritchler, Song Liu, Theresa Hahn, Lara E Sucheston-Campbell
Multiple candidate gene association studies of non-HLA single nucleotide polymorphisms (SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality, progression-free survival, transplant-related mortality and/or overall survival after BMT. Replication and validation of these SNP associations were performed using DISCOVeRY-BMT, a well-powered genome-wide association study consisting of two cohorts, totaling 2,883 BMT recipients with AML, ALL or MDS and their HLA-matched unrelated donors, treated from 2000-2011 and reported to the CIBMTR...
August 15, 2017: Blood
https://www.readbyqxmd.com/read/28674027/increasing-use-of-allogeneic-hematopoietic-cell-transplantation-in-patients-aged-70-years-and-older-in-the-united-states
#5
Lori Muffly, Marcelo C Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu, Kehinde Adekola, Mahmoud Aljurf, Karen K Ballen, Ashish Bajel, Frederic Baron, Minoo Battiwalla, Amer Beitinjaneh, Jean-Yves Cahn, Mathew Carabasi, Yi-Bin Chen, Saurabh Chhabra, Stefan Ciurea, Edward Copelan, Anita D'Souza, John Edwards, James Foran, Cesar O Freytes, Henry C Fung, Robert Peter Gale, Sergio Giralt, Shahrukh K Hashmi, Gerhard C Hildebrandt, Vincent Ho, Ann Jakubowski, Hillard Lazarus, Marlise R Luskin, Rodrigo Martino, Richard Maziarz, Philip McCarthy, Taiga Nishihori, Rebecca Olin, Richard F Olsson, Attaphol Pawarode, Edward Peres, Andrew R Rezvani, David Rizzieri, Bipin N Savani, Harry C Schouten, Mitchell Sabloff, Matthew Seftel, Sachiko Seo, Mohamed L Sorror, Jeff Szer, Baldeep M Wirk, William A Wood, Andrew Artz
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell transplantation (HCT) in adults ≥70 years with hematologic malignancies across the United States. Adults ≥70 years with a hematologic malignancy undergoing first allogeneic HCT in the United States between 2000 and 2013 and reported to the Center for International Blood and Marrow Transplant Research were eligible. Transplant utilization and transplant outcomes, including overall survival (OS), progression-free survival (PFS), and transplant-related mortality (TRM) were studied...
August 31, 2017: Blood
https://www.readbyqxmd.com/read/28606646/current-use-and-trends-in-hematopoietic-cell-transplantation-in-the-united-states
#6
EDITORIAL
Anita D'Souza, Stephanie Lee, Xiaochun Zhu, Marcelo Pasquini
Hematopoietic Cell Transplantation (HCT) is an established curative treatment for a number of malignant and nonmalignant diseases involving the hematopoietic system and some solid tumors. In this report, we provide information about the number of HCT procedures performed in the United States in 2015, and analyze trends and outcomes of HCT as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We show that the number of HCTs performed annually continues to increase, as the indications for HCT, preferred donor sources, and graft-versus-host prophylaxis continue to evolve...
September 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28606176/rituximab-containing-reduced-intensity-conditioning-improves-progression-free-survival-following-allogeneic-transplantation-in-b-cell-non-hodgkin-lymphoma
#7
Narendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, Madan Jagasia, Alyssa DiGilio, Steven M Devine, Samantha Jaglowski, Vanessa Kennedy, Andrew R Rezvani, Sonali M Smith, Anna Sureda, Timothy S Fenske, Mohamed A Kharfan-Dabaja, Phillipe Armand, Mehdi Hamadani
BACKGROUND: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-NHL. METHODS: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens...
June 12, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28529613/long-term-outcome-of-inflammatory-breast-cancer-compared-to-non-inflammatory-breast-cancer-in-the-setting-of-high-dose-chemotherapy-with-autologous-hematopoietic-cell-transplantation
#8
Yee Chung Cheng, Yushu Shi, Mei-Jie Zhang, Ruta Brazauskas, Michael T Hemmer, Michael R Bishop, Yago Nieto, Edward Stadtmauer, Lois Ayash, Robert Peter Gale, Hillard Lazarus, Leona Holmberg, Michael Lill, Richard F Olsson, Baldeep Mona Wirk, Mukta Arora, Parameswaran Hari, Naoto Ueno
Introduction: Inflammatory breast cancer (IBC) is a rare aggressive form of breast cancer. It is well known that the long-term survival and progression-free survival of IBC are worse than that of non-IBC. We report the long term outcomes of patients with IBC and non-IBC who had undergone high-dose chemotherapy (HDC) with autologous hematopoietic cell transplantation (AHCT). Methods: All 3387 patients with IBC or non-IBC who underwent HDC with AHCT between1990-2002 and registered with CIBMTR were included in this analysis...
2017: Journal of Cancer
https://www.readbyqxmd.com/read/28472539/hispanics-have-the-lowest-stem-cell-transplant-utilization-rate-for-autologous-hematopoietic-cell-transplantation-for-multiple-myeloma-in-the-united-states-a-cibmtr-report
#9
Jeffrey R Schriber, Parameswaran N Hari, Kwang Woo Ahn, Mingwei Fei, Luciano J Costa, Mohamad A Kharfan-Dabaja, Miguel Angel-Diaz, Robert P Gale, Siddharatha Ganguly, Saulius K Girnius, Shahrukh Hashmi, Attaphol Pawarode, David H Vesole, Peter H Wiernik, Baldeep M Wirk, David I Marks, Taiga Nishihori, Richard F Olsson, Saad Z Usmani, Tomer M Mark, Yago L Nieto, Anita D'Souza
BACKGROUND: Race/ethnicity remains an important barrier in clinical care. The authors investigated differences in the receipt of autologous hematopoietic cell transplantation (AHCT) among patients with multiple myeloma (MM) and outcomes based on race/ethnicity in the United States. METHODS: The Center for International Blood and Marrow Transplant Research database was used to identify 28,450 patients who underwent AHCT for MM from 2008 through 2014. By using data from the National Cancer Institute's Surveillance, Epidemiology, and End Results 18 registries, the incidence of MM was calculated, and a stem cell transplantation utilization rate (STUR) was derived...
August 15, 2017: Cancer
https://www.readbyqxmd.com/read/28450183/hematopoietic-stem-cell-transplantation-activity-in-pediatric-cancer-between-2008-and-2014-in-the-united-states-a-center-for-international-blood-and-marrow-transplant-research-report
#10
Pooja Khandelwal, Heather R Millard, Elizabeth Thiel, Hisham Abdel-Azim, Allistair A Abraham, Jeffery J Auletta, Farid Boulad, Valerie I Brown, Bruce M Camitta, Ka Wah Chan, Sonali Chaudhury, Morton J Cowan, Miguel Angel-Diaz, Shahinaz M Gadalla, Robert Peter Gale, Gregory Hale, Kimberly A Kasow, Amy K Keating, Carrie L Kitko, Margaret L MacMillan, Richard F Olsson, Kristin M Page, Adriana Seber, Angela R Smith, Anne B Warwick, Baldeep Wirk, Parinda A Mehta
This Center for International Blood and Marrow Transplant Research report describes the use of hematopoietic stem cell transplantation (HSCT) in pediatric patients with cancer, 4408 undergoing allogeneic (allo) and3076 undergoing autologous (auto) HSCT in the United States between 2008 and 2014. In both settings, there was a greater proportion of boys (n = 4327; 57%), children < 10 years of age (n = 4412; 59%), whites (n = 5787; 77%), and children with a performance score ≥ 90% at HSCT (n = 6187; 83%)...
August 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28411175/risk-factors-for-subsequent-central-nervous-system-tumors-in-pediatric-allogeneic-hematopoietic-cell-transplant-a-study-from-the-center-for-international-blood-and-marrow-transplant-research-cibmtr
#11
Melissa Gabriel, Bronwen E Shaw, Ruta Brazauskas, Min Chen, David A Margolis, Henrik Sengelov, Ann Dahlberg, Ibrahim A Ahmed, David Delgado, Hillard M Lazarus, Brenda Gibson, Kasiani C Myers, Rammurti T Kamble, Aly Abdel-Mageed, Chi-Kong Li, Mary E D Flowers, Minoo Battiwalla, Bipin N Savani, Navneet Majhail, Peter J Shaw
Survivors of hematopoietic cell transplantation (HCT) are at risk of subsequent solid tumors, including central nervous system (CNS) tumors. The risk of CNS tumors after HCT in pediatric HCT recipients is not known. We evaluated the incidence and risk factors for CNS tumors in pediatric recipients of allogeneic HCT reported to the Center for International Blood and Marrow Transplant Research between 1976 and 2008. A case control design was used. There were no CNS tumors in the nonmalignant cohort (n = 4543) or in those undergoing HCT for solid tumors (n = 26)...
August 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28389255/relative-telomere-length-before-hematopoietic-cell-transplantation-and-outcome-after-unrelated-donor-hematopoietic-cell-transplantation-for-acute-leukemia
#12
Youjin Wang, Tao Wang, Casey Dagnall, Michael Haagenson, Stephen R Spellman, Belynda Hicks, Kristine Jones, Stephanie J Lee, Sharon A Savage, Shahinaz M Gadalla
Telomeres are tandem nucleotide repeats and a protein complex located at the end of the chromosomes maintaining genomic stability. Their potential as a predictive biomarker for outcomes after allogeneic hematopoietic cell transplant (HCT) in hematologic malignancies is still unclear. From the Center for International Blood and Marrow Transplant Research we randomly selected 536 acute leukemia patients from those who underwent myeloablative 8/8 HLA-matched unrelated donor HCT between 2005 and 2012 and who had an available pre-HCT blood sample in the repository...
July 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28346419/evolving-concepts-in-prognostic-scoring-of-chronic-gvhd
#13
REVIEW
A Lazaryan, M Arora
Chronic GvHD (cGvHD) remains one of the most complex and challenging complications after allogeneic hematopoietic cell transplantation. Emerging knowledge about the clinical manifestations and associated organ involvement of cGvHD has led to the establishment of prognostic parameters for post-transplant survival among affected allograft recipients. Studies employing the pre-National Institutes of Health (NIH) consensus data on cGvHD incidence and its risks have led to development of the CIBMTR's cGvHD risk stratification, which serves as the most refined and validated prognostic tool for estimating survival of patients with cGvHD...
March 27, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28214979/improved-prognostic-stratification-power-of-cibmtr-risk-score-with-the-addition-of-absolute-lymphocyte-and-eosinophil-counts-at-the-onset-of-chronic-gvhd
#14
Joon Ho Moon, Nada Hamad, Sang Kyun Sohn, Jieun Uhm, Naheed Alam, Vikas Gupta, Jeffrey H Lipton, Hans A Messner, Matthew Seftel, John Kuruvilla, Dennis Dong Hwan Kim
The CIBMTR chronic graft-versus-host disease (cGVHD) risk score can be refined and improved for better prognostic stratification. Three hundred and seven consecutive patients diagnosed with cGVHD by the NIH consensus criteria were retrospectively reviewed and had the CIBMTR risk score applied and analyzed. The CIBMTR risk score was successfully validated in our cohort (n = 307). The 3-year overall survival (OS) rates in each risk group (RG) were 82.5 ± 11.3% (RG1), 79.4 ± 3.0% (RG2), 71.8 ± 6.3% (RG3), and 27...
May 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28161608/allogeneic-hematopoietic-cell-transplantation-for-aggressive-nk-cell-leukemia-a-center-for-international-blood-and-marrow-transplant-research-analysis
#15
Mehdi Hamadani, Abraham S Kanate, Alyssa DiGilio, Kwang Woo Ahn, Sonali M Smith, Jong Wook Lee, Ernesto Ayala, Nelson Chao, Parameswaran Hari, Javier Bolaños-Meade, Ronald Gress, Niels Smedegaard Anderson, Yi-Bin Chen, Umar Farooq, Gary Schiller, Jean Yared, Anna Sureda, Timothy S Fenske, Horatiu Olteanu
Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease...
May 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28119528/outcomes-of-ucb-transplantation-are-comparable-in-flt3-aml-results-of-cibmtr-eurocord-and-ebmt-collaborative-analysis
#16
C Ustun, F Giannotti, M-J Zhang, H-L Wang, C Brunstein, M Labopin, V Rocha, M de Lima, F Baron, B M Sandmaier, M Eapen, E Gluckman, A Nagler, D J Weisdorf, A Ruggeri
Allogeneic hematopoietic cell transplantation (HCT) from siblings or unrelated donors (URD) during complete remission (CR) may improve leukemia-free survival (LFS) in FMS-like tyrosine kinase 3+ (FLT3+) acute myeloid leukemia (AML), which has poor prognosis because of high relapse rates. Umbilical cord blood (UCB) HCT outcomes are largely unknown in this population. We found that compared with sibling HCT, relapse risks were similar after UCB (n=126) (hazard ratio (HR) 0.86, P=0.54) and URD (n=91) (HR 0.81, P=0...
June 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28115276/allogeneic-hematopoietic-cell-transplantation-for-adult-chronic-myelomonocytic-leukemia
#17
Hien Duong Liu, Kwang Woo Ahn, Zhen-Huan Hu, Mehdi Hamadani, Taiga Nishihori, Baldeep Wirk, Amer Beitinjaneh, David Rizzieri, Michael R Grunwald, Mitchell Sabloff, Richard F Olsson, Ashish Bajel, Christopher Bredeson, Andrew Daly, Yoshihiro Inamoto, Navneet Majhail, Ayman Saad, Vikas Gupta, Aaron Gerds, Adriana Malone, Martin Tallman, Ran Reshef, David I Marks, Edward Copelan, Usama Gergis, Mary Lynn Savoie, Celalettin Ustun, Mark R Litzow, Jean-Yves Cahn, Tamila Kindwall-Keller, Gorgun Akpek, Bipin N Savani, Mahmoud Aljurf, Jacob M Rowe, Peter H Wiernik, Jack W Hsu, Jorge Cortes, Matt Kalaycio, Richard Maziarz, Ronald Sobecks, Uday Popat, Edwin Alyea, Wael Saber
Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for patients with chronic myelomonocytic leukemia (CMML); however, few data exist regarding prognostic factors and transplantation outcomes. We performed this retrospective study to identify prognostic factors for post-transplantation outcomes. The CMML-specific prognostic scoring system (CPSS) has been validated in subjects receiving nontransplantation therapy and was included in our study. From 2001 to 2012, 209 adult subjects who received HCT for CMML were reported to the Center for International Blood and Marrow Transplant Research...
May 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/27991895/pre-existing-invasive-fungal-infection-is-not-a-contraindication-for-allogeneic-hsct-for-patients-with-hematologic-malignancies-a-cibmtr-study
#18
R T Maziarz, R Brazauskas, M Chen, A A McLeod, R Martino, J R Wingard, M Aljurf, M Battiwalla, C C Dvorak, B Geroge, E C Guinan, G A Hale, H M Lazarus, J-W Lee, J L Liesveld, M Ramanathan, V Reddy, B N Savani, F O Smith, L Strasfeld, R A Taplitz, C Ustun, M J Boeckh, J Gea-Banacloche, C A Lindemans, J J Auletta, M L Riches
Patients with prior invasive fungal infection (IFI) increasingly proceed to allogeneic hematopoietic cell transplantation (HSCT). However, little is known about the impact of prior IFI on survival. Patients with pre-transplant IFI (cases; n=825) were compared with controls (n=10247). A subset analysis assessed outcomes in leukemia patients pre- and post 2001. Cases were older with lower performance status (KPS), more advanced disease, higher likelihood of AML and having received cord blood, reduced intensity conditioning, mold-active fungal prophylaxis and more recently transplanted...
February 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27941764/gvhd-after-umbilical-cord-blood-transplantation-for-acute-leukemia-an-analysis-of-risk-factors-and-effect-on-outcomes
#19
Y-B Chen, T Wang, M T Hemmer, C Brady, D R Couriel, A Alousi, J Pidala, A Urbano-Ispizua, S W Choi, T Nishihori, T Teshima, Y Inamoto, B Wirk, D I Marks, H Abdel-Azim, L Lehmann, L Yu, M Bitan, M S Cairo, M Qayed, R Salit, R P Gale, R Martino, S Jaglowski, A Bajel, B Savani, H Frangoul, I D Lewis, J Storek, M Askar, M A Kharfan-Dabaja, M Aljurf, O Ringden, R Reshef, R F Olsson, S Hashmi, S Seo, T R Spitzer, M L MacMillan, A Lazaryan, S R Spellman, M Arora, C S Cutler
Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we analyzed 1404 umbilical cord blood transplantation (UCBT) patients (single (<18 years)=810, double (⩾18 years)=594) with acute leukemia to define the incidence of acute GvHD (aGvHD) and chronic GvHD (cGvHD), analyze clinical risk factors and investigate outcomes. After single UCBT, 100-day incidence of grade II-IV aGvHD was 39% (95% confidence interval (CI), 36-43%), grade III-IV aGvHD was 18% (95% CI, 15-20%) and 1-year cGvHD was 27% (95% CI, 24-30%)...
March 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/27712033/reduced-intensity-conditioned-allograft-yields-favorable-survival-for-older-adults-with-b-cell-acute-lymphoblastic-leukemia
#20
MULTICENTER STUDY
Ashley Rosko, Hai-Lin Wang, Marcos de Lima, Brenda Sandmaier, H Jean Khoury, Andrew Artz, Johnathan Brammer, Christopher Bredeson, Sherif Farag, Mohamed Kharfan-Dabaja, Hillard M Lazarus, David I Marks, Rodrigo Martino Bufarull, Joseph McGuirk, Mohamed Mohty, Taiga Nishihori, Ian Nivison-Smith, Armin Rashidi, Olle Ringden, Matthew Seftel, Daniel Weisdorf, Veronika Bachanova, Wael Saber
Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes. Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55-72) with B-ALL with disease status in CR1 (71%), >CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor (59%) or HLA-matched sibling (32%)...
January 2017: American Journal of Hematology
keyword
keyword
115199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"